 | Up a level |
Soria, Jean-Charles, Tan, Daniel S. W., Chiari, Rita, Wu, Yi-Long 
ORCID: 0000-0002-3611-0258, Paz-Ares, Luis, Wolf, Juergen, Geater, Sarayut L., Orlov, Sergey ORCID: 0000-0001-6080-8042, Cortinovis, Diego, Yu, Chong-Jen ORCID: 0000-0001-5664-9392, Hochmair, Maximillian, Cortot, Alexis B., Tsai, Chun-Ming, Moro-Sibilot, Denis, Campelo, Rosario G., McCulloch, Tracey, Sen, Paramita, Dugan, Margaret, Pantano, Serafino, Branle, Fabrice, Massacesi, Cristian and de Castro, Gilberto, Jr.
(2017).
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Lancet, 389 (10072).
S. 917 - 930.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-547X
Janne, Pasi A., van den Heuvel, Michel M., Barlesi, Fabrice, Cobo, Manuel, Mazieres, Julien, Crino, Lucio, Orlov, Sergey ORCID: 0000-0001-6080-8042, Blackhall, Fiona ORCID: 0000-0001-8716-3395, Wolf, Juergen, Garrido, Pilar, Poltoratskiy, Artem, Mariani, Gabriella, Ghiorghiu, Dana, Kilgour, Elaine, Smith, Paul, Kohlmann, Alexander, Carlile, David J., Lawrence, David, Bowen, Karin and Vansteenkiste, Johan
(2017).
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial.
JAMA-J. Am. Med. Assoc., 317 (18).
S. 1844 - 1854.
CHICAGO:
AMER MEDICAL ASSOC.
ISSN 1538-3598